|
Brainstorm Cell Therapeutics Inc. (BCLI) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Brainstorm Cell Therapeutics Inc. (BCLI) Bundle
Enhance your investment strategies with the (BCLI) DCF Calculator! Utilize real financial data from Brainstorm Cell Therapeutics Inc., adjust growth projections and expenses, and instantly observe how these modifications affect the intrinsic value of (BCLI).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .8 | .8 | .8 | .8 | .8 | .8 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -31.5 | -24.3 | -24.0 | -16.9 | .0 | .7 | .7 | .7 | .7 | .7 |
| EBITDA, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Depreciation | .2 | .3 | .3 | .3 | .0 | .7 | .7 | .7 | .7 | .7 |
| Depreciation, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| EBIT | -31.7 | -24.5 | -24.3 | -17.2 | .0 | .7 | .7 | .7 | .7 | .7 |
| EBIT, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Total Cash | 41.9 | 22.1 | 3.0 | 1.3 | .2 | .7 | .7 | .7 | .7 | .7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .3 | .1 | .1 | .1 | .1 | .7 | .7 | .7 | .7 | .7 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 7.42 | 81.48 | 81.48 | 81.48 | 81.48 | 81.48 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .7 | .7 | .7 | .7 | .7 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 5.4 | 3.7 | 6.2 | 5.0 | 6.1 | .8 | .8 | .8 | .8 | .8 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 716.14 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.4 | -.3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -31.7 | -24.5 | -24.3 | -17.2 | .0 | .7 | .7 | .7 | .7 | .7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -26.7 | -26.1 | -21.5 | -18.2 | 1.1 | -5.2 | 1.4 | 1.4 | 1.4 | 1.4 |
| WACC, % | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1 | |||||||||
| Terminal Value | 31 | |||||||||
| Present Terminal Value | 22 | |||||||||
| Enterprise Value | 22 | |||||||||
| Net Debt | 1 | |||||||||
| Equity Value | 21 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | 4.00 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Brainstorm Cell Therapeutics Inc.'s (BCLI) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Innovative Drug Development Pipeline: Focuses on advanced therapies for neurological disorders, showcasing a robust pipeline.
- Proprietary Technology Platforms: Utilizes cutting-edge technologies for cell-based treatments and regenerative medicine.
- Customizable Research Assumptions: Adjust parameters related to market potential, clinical trial timelines, and funding requirements.
- Comprehensive Financial Metrics: Evaluate key performance indicators, including R&D expenses and revenue forecasts for Brainstorm Cell Therapeutics Inc. (BCLI).
- Interactive Dashboards and Visualizations: Dynamic charts provide clear insights into clinical and financial data for informed decision-making.
How It Works
- Step 1: Download the prebuilt Excel template containing Brainstorm Cell Therapeutics Inc.'s (BCLI) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Brainstorm Cell Therapeutics Inc.'s (BCLI) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose Brainstorm Cell Therapeutics Inc. (BCLI)?
- Innovative Solutions: Pioneering research in cell therapy for neurological diseases.
- Proven Expertise: A team of industry leaders dedicated to advancing therapeutic options.
- Robust Pipeline: A diverse range of promising treatments in various stages of development.
- Commitment to Quality: Adherence to the highest standards in clinical trials and product development.
- Community Focused: Engaging with patients and stakeholders to drive meaningful impact.
Who Should Use This Product?
- Investors: Assess Brainstorm Cell Therapeutics Inc. (BCLI)’s valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts for BCLI.
- Biotech Entrepreneurs: Understand how biotech firms like Brainstorm Cell Therapeutics Inc. (BCLI) are valued in the market.
- Consultants: Provide expert valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize real-time data to learn and teach valuation practices in biotechnology.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Brainstorm Cell Therapeutics Inc. (BCLI) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Brainstorm Cell Therapeutics Inc. (BCLI).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.